Uncategorized

CANTON, Mich. and SHANGHAI (May 5, 2020) – MMS announced that a successful collaboration with Shanghai-based Green Valley Pharmaceutical Co. (Green Valley) resulted in gaining U.S. Food & Drug Administration (FDA) approval of an Investigational New Drug (IND) application for the GV-971 international multi-center Phase III clinical study in the treatment of patients with Alzheimer’s disease.

Canton, Mich. (March 20, 2020) — MMS Holdings announced today that it is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or other global health authorities.

by Prasad M. Koppolu, March 12, 2020
I would like to take a moment and share our commitment to the highest levels of health and improving lives worldwide, amidst the outbreak of COVID-19.

CANTON, Mich. (March 4, 2020) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that the Datacise Integrated Safety Explorer will make its debut at the 2020 PHUSE U.S. Connect conference in Orlando, Florida as part of the PHUSE/FDA Data Science Innovation Challenge, where, according to PHUSE, the “greatest minds in the data sciences arena come together and collaborate.”

BLOEMFONTEIN, South Africa (November 20, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that its regional operations in South Africa has more than doubled in the past fiscal year, through the addition of new colleagues in Bloemfontein and the successful procurement of key contracts with clinical trial sponsors and research groups.

CANTON, Mich. (October 23, 2019) – MMS Holdings – an award-winning, data-focused CRO – announced today that its Executive Director of Global Operations Michelle Gayari has joined the advisory board for the international 501(c)(3) charity Together Educating All Children in Hospitals (TEACH). As its sole board member in the state of Michigan, Gayari will provide leadership, guidance, and fundraising support to help in bringing exciting, hands-on educational programs to children in hospitals.

CANTON, Mich. (October 10, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced its recognition as a finalist in the highly-esteemed, global Scrip Awards by Informa Pharma Intelligence as Best Contract Research Organization – Specialist Providers at the 10th Annual MMS Scientific Symposium.

CANTON, Mich. (September 30, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – celebrated another successful collaboration with Oracle Health Sciences and a specialized Oncology pharmaceutical company. MMS will share their learnings with peers at the Society for Clinical Data Management (SCDM) annual meeting in Baltimore, Md.

CANTON, Mich. (September 10, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – was recently announced as an honorable mention recipient of PR Daily’s Corporate Social Responsibility Awards in the Engagement & Communications category for its #OneMMS volunteer campaign.

CANTON, Mich. and FRISCO, Texas (August 1, 2019) – MMS Holdings – an award-winning, data-focused CRO – announced that today marks 10 years of successful partnership with Sage IT—a premier provider, helping companies operationalize their vision through the enhancement or development of innovative technology solutions.

CANTON, Mich. (June 27, 2019) – MMS announced today the launch of Automatiqc™ (pronounced: automatic). Automatiqc is a new cloud-based application that automatically performs quality control (QC) and style checks for medical writing, pharmacovigilance, clinical trial transparency, and other types of documents in the pharmaceutical, biotechnology, and medical device industries.

SEATTLE (May 23, 2019) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today the addition of Dr. Mike Poole, MD, FACP to its board of scientific advisors. Currently a venture partner at Biomatics Capital, Inc., Dr. Poole has more than 25 years of experience in the pharmaceutical industry, most recently having led external investments in the Office of the President for Global Health at the Bill and Melinda Gates Foundation.